LPC
RCKT icon

Lion Point Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Lion Point Capital’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Hold
86,000
– – 1.41% 25
2026
Q1 		$308K Hold
86,000
– – 1.84% 22
2025
Q4 		$302K Hold
86,000
– – 1.56% 30
2025
Q3 		$280K Buy
+86,000
New +$271K 1.59% 24

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Lion Point Capital's RCKT Position: Q2 2026 in Review

Lion Point Capital held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 86,000 shares worth $294K. The position accounts for 1.41% of the portfolio, ranked #25.

Lion Point Capital first reported a position in RCKT in Q3 2025 and has held it in 4 quarters since. The position peaked at $308K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Lion Point Capital held 86,000 shares of Rocket Pharmaceuticals worth $294K as of Q2 2026.
  • Lion Point Capital left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up 1.41% of Lion Point Capital's portfolio in Q2 2026, its #25 holding.
  • Lion Point Capital first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Lion Point Capital's Rocket Pharmaceuticals position peaked at $308K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.